Abeona Treats First Commercial Patient With FDA-Approved ZEVASKYN Gene Therapy For RDEB At Stanford’s Lucile Packard Children’s Hospital

Abeona Therapeutics Inc. has announced that its first commercial patient has been treated with ZEVASKYN (prademagene zamikeracel), the recently FDA-approved gene therapy developed for people living with recessive dystrophic epidermolysis bullosa (RDEB). This treatment represents an important step forward for patients who suffer from this rare and serious genetic condition, which causes fragile skin and chronic wounds. ZEVASKYN is an autologous gene therapy, meaning it is created using a patient’s own cells, and is designed to support the healing of wounds in both adults and children with RDEB. The first treatment was carried out at Lucile Packard Children’s Hospital Stanford in Palo Alto, California.

According to Vish Seshadri, Chief Executive Officer of Abeona Therapeutics, administering the first commercial dose marks a significant milestone for the company. He noted that this achievement reflects years of dedication and hard work from the Abeona team. Seshadri also expressed appreciation for the expanding network of Qualified Treatment Centers that are helping bring ZEVASKYN to patients. He added that more individuals are already scheduled to receive treatment in the coming year, indicating strong momentum in the therapy’s rollout.

Dr. Joyce Teng, professor of dermatology at Stanford Medicine and chief of pediatric dermatology at Stanford Medicine Children’s Health, underlined the importance of advancing treatment options for RDEB. She explained that patients with this condition endure lifelong pain and require extensive wound care, making new therapies essential in improving their quality of life. Dr. Teng reaffirmed the commitment of her team to pursuing treatments that offer meaningful care and renewed hope for patients and their families.